Effects of adrenal steroids on basal ganglia neuropeptide mRNA and tyrosine hydroxylase radioimmunoreactive levels in the adrenalectomized rat.
To investigate the effects of type I (mineralocorticoid) and type II (glucocorticoid) receptor activation on striatal neuropeptide [preproenkephalin (PPE), preprotachykinin (PPT), and preprodynorphin (DYN)] mRNA and midbrain cholecystokinin (CCK) mRNA as well as striatal tyrosine hydroxylase radioimmunoreactivity (TH-RIC) levels, we administered either replacement levels of corticosterone (CORT; 0.5 mg/kg/day, s.c.) or pharmacological levels of deoxycorticosterone acetate (DOCA; a mineralocorticoid steroid with ability to bind to type I and type II receptors; 5 mg/kg, s.c.) to adrenalectomized adult male rats. After 1 week of recovery from adrenalectomy surgery, animals were injected daily with sesame oil or CORT for 1, 3, or 7 days or DOCA for 3 or 7 days and killed 16 h after the last injection. Adrenalectomy resulted in a decrease in all three striatal neuropeptide mRNA levels, compared with sham-operated rats. CORT replacement resulted in recovered PPE and PPT mRNA levels after 1 day and elevated PPE mRNA levels over those in sham-operated controls after 3 days. In contrast, DYN mRNA levels showed recovery after 7 days of CORT replacement. Results after DOCA treatment largely paralleled those after CORT replacement. There were no significant treatment effects on indirect markers of midbrain dopaminergic activity, i.e., CCK mRNA and TH-RIC. From these results we conclude that compared with striatal tachykinin and dynorphinergic neurons, enkephalinergic cells show greater sensitivity, whereas the dopaminergic system, including mesencephalic CCK, demonstrates an insensitivity to physiological CORT and to pharmacological DOCA treatment.
Laboratory of Neuroendocrinology, Rockefeller University, New York, New York 10021, USA.
L R
LR
Lucas
P
P
Pompei
J
J
Ono
B S
BS
McEwen
D000315:Adrenalectomy; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000494:pharmacology*; D001479:Basal Ganglia / Q000737:chemistry* / Q000201:enzymology; D002766:Cholecystokinin / Q000235:genetics; D003345:Corticosterone / Q000494:pharmacology*; D003900:Desoxycorticosterone / Q000494:pharmacology; D004399:Dynorphins / Q000235:genetics; D004745:Enkephalins / Q000235:genetics; D015870:Gene Expression / Q000187:drug effects / Q000502:physiology; D008297:Male; D009479:Neuropeptides / Q000235:genetics*; D011498:Protein Precursors / Q000235:genetics; D012333:RNA, Messenger / Q000378:metabolism; D011863:Radioimmunoassay; D051381:Rats; D017207:Rats, Sprague-Dawley; D015320:Tachykinins / Q000235:genetics; D014446:Tyrosine 3-Monooxygenase / Q000378:metabolism*
D000893:Anti-Inflammatory Agents; D004745:Enkephalins; D009479:Neuropeptides; D011498:Protein Precursors; D012333:RNA, Messenger; D015320:Tachykinins; C036448:pre-prodynorphin; C044206:preprotachykinin; D003900:Desoxycorticosterone; D004399:Dynorphins; D002766:Cholecystokinin; C033660:preproenkephalin; D014446:Tyrosine 3-Monooxygenase; D003345:Corticosterone